A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome

Inclusion Criteria: * Signed informed consent * male aged 30 to 70 years of age * LDL-C \<6 mmol/L * HDL-C ≤1.2 mmol/L * at least 2 of the following: * insulin resistance (fasting glucose \>6 mmol/L or insulin \>10 mU/L or HOMA score \>2.5) * central obesity (waist circumference \>=94 cm). * plasma triglycerides \>=1.7 and \<4.5 mmol/L. * blood pressure \>=130/ \>=85 mm Hg or on drug treatment for hypertension Exclusion Criteria: * LDL cholesterol \>=6 mmol/L * pre-existing or history of cardiovascular disease, diabetes, renal dysfunction, anaemia, history of significant dyspepsia or gastrointestinal disease * apolipoprotein genotype E2/E2